Media Center

Introduction Recombinant protein production is essential for pharmaceutical development, diagnostics, and industrial applications. However, achieving high yields of soluble, active proteins – especially for difficult-to-express targets – remains a significant challenge. This article explores advanced solutions for cost-effective protein production, from overcoming expression limitations in standard E. coli strains to implementing extracellular secretion strategies that simpli

Discover the ground-breaking ECOnti project, where enGenes Biotech and partners have developed an integrated continuous manufacturing process that’s transforming biotechnology production. See how multiple industry partners have come together to create a seamless, continuous manufacturing system that enhances efficiency, reduces costs, and advances the future of biotechnology manufacturing. To watch the video, clink on this link: https://www.pharmaceutical-networking.com/econt

When nucleic acid contamination in protein purification isn’t controlled, you face sticky lysates, slower chromatography, and reduced protein yield. Residual DNA also risks regulatory non-compliance. Learn how using endonucleases effectively can streamline processes, reduce unit economics, and make nuclease treatment a practical solution from early development to large-scale manufacturing. From uncovering how proteins work at the bench to developing therapeutic biologics or s

Recombinant proteins and genetics specialist CDMO enGenes Biotech has embarked on a potentially transformational project to create a platform for continuous automated production of plasmid DNA (pDNA). The iCAP Project (Integrated Continuous and Automated Platform for Plasmid Production) is partly consequent from the success of the ECOnti collaboration for continuous protein production that united enGenes with development partners novasign® and Qubicon® AG to pioneer continuou

Within biotech, it's hard to think of an application that doesn’t involve proteins in some way or another. Whether it's research to identify and characterize proteins of interest, structural biology, development of a therapeutic protein or industrial fermentation, protein purification will be a key part of the workflow.   Many approaches to protein purification exist and one step common to all is the need to eliminate host nucleic acids that are released during the process. W

enGenes Biotech has created a portfolio of high-performance products to transform bioprocessing — from upstream fermentation to downstream purification. The portfolio includes a cost-effective endonuclease and a versatile range of affinity ligands, all produced using the proprietary enGenes-eXpress™, -eXtra™, and -eXcite™ platforms to deliver reliability, scalability, and efficiency. -eXrase™, ™ for smart DNA digestion, Real Cost Savings -eXrase™, is a next-generation recombi

This whitepaper introduces the enGenes-expand technology, the site-specific incorporation of non-canonical amino acids (NCAAs) by amber-stop codon suppression. This technology has vast applications in fields like protein engineering, drug discovery, and biotechnology, by enabling the synthesis of modified proteins with tailored properties, as well as the cost-effective incorporation of NCAAs into proteins for bioconjugation through click-chemistry. This approach, which overla

enGenes Biotech has developed -eXchange™ as an optimized solution for the cost-effective production of recombinant proteins and plasmid DNA that are free of antibiotic resistance genes. It can be used in conjunction with other enGenes technology platforms, such as -eXpress™ and enGenes-eXtra™ for enhanced production of very high-quality plasmid DNA (pDNA) and recombinant proteins, allowing for faster-track production of enzymes and antigen development, for instance. enGenes-e

The latest White Paper from advanced biotechnological solutions developer enGenes Biotech discusses solutions for improving the efficacy, safety and production yields of plasmid DNA. The technical article Advancing Plasmid DNA Manufacturing is authored by enGenes Biotech CEO and CSO Dr. Juergen Mairhofer. It introduces the enGenes -eXcess™ and enGenes -eXchange™ technologies as groundbreaking advances that improve production yields with up to 3 g/l of supercoiled plasmid DNA,